307 related articles for article (PubMed ID: 17379095)
21. Chromatin accessibility promotes hematopoietic and leukemia stem cell activity.
Cabal-Hierro L; van Galen P; Prado MA; Higby KJ; Togami K; Mowery CT; Paulo JA; Xie Y; Cejas P; Furusawa T; Bustin M; Long HW; Sykes DB; Gygi SP; Finley D; Bernstein BE; Lane AA
Nat Commun; 2020 Mar; 11(1):1406. PubMed ID: 32179749
[TBL] [Abstract][Full Text] [Related]
22. Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis.
Corces-Zimmerman MR; Majeti R
Leukemia; 2014 Dec; 28(12):2276-82. PubMed ID: 25005245
[TBL] [Abstract][Full Text] [Related]
23. Survival regulation of leukemia stem cells.
Hu Y; Li S
Cell Mol Life Sci; 2016 Mar; 73(5):1039-50. PubMed ID: 26686687
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells.
An N; Khan S; Imgruet MK; Jueng L; Gurbuxani S; McNerney ME
Oncogene; 2023 Mar; 42(12):881-893. PubMed ID: 36725889
[TBL] [Abstract][Full Text] [Related]
25. HoxA10 activates CDX4 transcription and Cdx4 activates HOXA10 transcription in myeloid cells.
Bei L; Huang W; Wang H; Shah C; Horvath E; Eklund E
J Biol Chem; 2011 May; 286(21):19047-64. PubMed ID: 21471217
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional control of leukemogenesis by the chromatin reader SGF29.
Barbosa K; Deshpande A; Perales M; Xiang P; Murad R; Pramod AB; Minkina A; Robertson N; Schischlik F; Lei X; Sun Y; Brown A; Amend D; Jeremias I; Doench JG; Humphries RK; Ruppin E; Shendure J; Mali P; Adams PD; Deshpande AJ
Blood; 2024 Feb; 143(8):697-712. PubMed ID: 38048593
[TBL] [Abstract][Full Text] [Related]
27. A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML.
Bamezai S; Pulikkottil AJ; Yadav T; Vegi NM; Mueller J; Mark J; Mandal T; Feder K; Ihme S; Song C; Rosler R; Wiese S; Hoell JI; Kloetgen A; Karsan A; Kumari A; Wojenski L; Sinha AU; Gonzalez-Menendez I; Quintanilla-Martinez L; Donato E; Trumpp A; Kruse E; Hamperl S; Zou L; Rawat VPS; Buske C
Blood; 2023 Jul; 142(1):90-105. PubMed ID: 37146239
[TBL] [Abstract][Full Text] [Related]
28. Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells.
Darley RL; Hoy TG; Baines P; Padua RA; Burnett AK
J Exp Med; 1997 Apr; 185(7):1337-47. PubMed ID: 9104820
[TBL] [Abstract][Full Text] [Related]
29. Unveiling myeloid transformation: T-LGLL with eosinophilia masking myeloid-associated STAT5B mutation culminating in AML.
Dong Q; Wang Y; Xiu Y; Wu X; O'Neill S; Meyerson H; Suske T; Moriggl R; Hu S; Wang W; Zhao C
Br J Haematol; 2024 Jun; 204(6):2487-2491. PubMed ID: 38508872
[No Abstract] [Full Text] [Related]
30. FLT3-Mutated Leukemic Stem Cells: Mechanisms of Resistance and New Therapeutic Targets.
Capelli D
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791898
[TBL] [Abstract][Full Text] [Related]
31. Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells.
van der Werf I; Mondala PK; Steel SK; Balaian L; Ladel L; Mason CN; Diep RH; Pham J; Cloos J; Kaspers GJL; Chan WC; Mark A; La Clair JJ; Wentworth P; Fisch KM; Crews LA; Whisenant TC; Burkart MD; Donohoe ME; Jamieson CHM
Cell Rep Med; 2023 Mar; 4(3):100962. PubMed ID: 36889320
[TBL] [Abstract][Full Text] [Related]
32. HOXB1 restored expression promotes apoptosis and differentiation in the HL60 leukemic cell line.
Petrini M; Felicetti F; Bottero L; Errico MC; Morsilli O; Boe A; De Feo A; Carè A
Cancer Cell Int; 2013 Oct; 13(1):101. PubMed ID: 24148231
[TBL] [Abstract][Full Text] [Related]
33. Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis.
Parenti S; Rontauroli S; Carretta C; Mallia S; Genovese E; Chiereghin C; Peano C; Tavernari L; Bianchi E; Fantini S; Sartini S; Romano O; Bicciato S; Tagliafico E; Della Porta M; Manfredini R
NPJ Precis Oncol; 2021 Feb; 5(1):4. PubMed ID: 33542466
[TBL] [Abstract][Full Text] [Related]
34. Missense mutations in Myc Box I influence nucleocytoplasmic transport to promote leukemogenesis.
Arthur NB; Christensen KA; Mannino K; Ruzinova MB; Kumar A; Gruszczynska A; Day RB; Erdmann-Gilmore P; Mi Y; Sprung R; York CR; Townsend RR; Spencer DH; Sykes SM; Ferraro F
Clin Cancer Res; 2024 Jun; ():. PubMed ID: 38848040
[TBL] [Abstract][Full Text] [Related]
35. HOXA9 and β-catenin safeguard HSC integrity.
Mapperley C; Kranc KR
Blood; 2024 Apr; 143(16):1554-1556. PubMed ID: 38635250
[No Abstract] [Full Text] [Related]
36. FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.
Chu SH; Heiser D; Li L; Kaplan I; Collector M; Huso D; Sharkis SJ; Civin C; Small D
Cell Stem Cell; 2012 Sep; 11(3):346-58. PubMed ID: 22958930
[TBL] [Abstract][Full Text] [Related]
37. Targeting FLT3 mutations in AML: review of current knowledge and evidence.
Daver N; Schlenk RF; Russell NH; Levis MJ
Leukemia; 2019 Feb; 33(2):299-312. PubMed ID: 30651634
[TBL] [Abstract][Full Text] [Related]
38. NOX-driven ROS formation in cell transformation of FLT3-ITD-positive AML.
Jayavelu AK; Moloney JN; Böhmer FD; Cotter TG
Exp Hematol; 2016 Dec; 44(12):1113-1122. PubMed ID: 27666490
[TBL] [Abstract][Full Text] [Related]
39. Genomic Classification and Prognosis in Acute Myeloid Leukemia.
Papaemmanuil E; Gerstung M; Bullinger L; Gaidzik VI; Paschka P; Roberts ND; Potter NE; Heuser M; Thol F; Bolli N; Gundem G; Van Loo P; Martincorena I; Ganly P; Mudie L; McLaren S; O'Meara S; Raine K; Jones DR; Teague JW; Butler AP; Greaves MF; Ganser A; Döhner K; Schlenk RF; Döhner H; Campbell PJ
N Engl J Med; 2016 Jun; 374(23):2209-2221. PubMed ID: 27276561
[TBL] [Abstract][Full Text] [Related]
40. FLT3ITD drives context-specific changes in cell identity and variable interferon dependence during AML initiation.
Li Y; Yang W; Patel RM; Casey EB; Denby E; Mendoza-Castrejon J; Rodriguez-Lopez P; Magee JA
Blood; 2023 Mar; 141(12):1442-1456. PubMed ID: 36395068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
